News
News, Syndication, Xconomy »
The Innovation Imperative: How Corporations and Nations Can Survive the Tsunami of Global Competition and Thrive | |
|
Posted by Mary Canady September 3rd, 2010 .
| |
| No Comments |
[[Click headline to continue reading.]]
News, Syndication, Xconomy »
Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb | |
|
Posted by Mary Canady September 2nd, 2010 .
| |
| No Comments |
[[Click headline to continue reading.]]
News, Syndication, Xconomy »
Otonomy Gets $38.5M, Avalon Helps Restart Drug for Age-Related Blindness, Accumetrics Heads Toward Profitability, & More San Diego Life Sciences News | |
|
Posted by Mary Canady September 2nd, 2010 .
| |
| No Comments |
[[Click headline to continue reading.]]
News, Syndication, Xconomy »
Accumetrics Adds $7 Million in Venture Funding, Plans to Reach Profitability | |
|
Posted by Mary Canady September 1st, 2010 .
| |
| No Comments |
[[Click headline to continue reading.]]
BioSpace, News, Syndication »
Genzyme Corporation And Isis Pharmaceuticals, Inc. Release: Data from Mipomersen Phase 3 Trial in heFH Patients Meets Primary Endpoint with 28 Percent LDL-C Reduction | |
|
Posted by BioSpace.com Featured News September 1st, 2010 .
| |
| No Comments |
BioSpace, News, Syndication »
Takeda Pharmaceutical Co. Ltd. And Orexigen Therapeutics, Inc. Sign $1 Billion Obesity Pact | |
|
Posted by BioSpace.com Featured News September 1st, 2010 .
| |
| No Comments |
SAN DIEGO and OSAKA, Japan, Sept. 2 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceutical Company Limited (TSE: 4502), today announced that they have entered into an exclusive partnership to develop and commercialize Contrave (naltrexone... More...
BioSpace, News, Syndication »
Cebix Raises $16M From Investors | |
|
Posted by BioSpace.com Featured News September 1st, 2010 .
| |
| No Comments |
BioSpace, News, Syndication »
MediciNova, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference | |
|
Posted by BioSpace.com Featured News September 1st, 2010 .
| |
| No Comments |
BioSpace, News, Syndication »
Optimer Pharmaceuticals, Inc. Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming Annual Meeting | |
|
Posted by BioSpace.com Featured News September 1st, 2010 .
| |
| No Comments |
SAN DIEGO, Sept. 2 /PRNewswire/ --Results from studies related to Optimer Pharmaceutocation">Boston on September 12-15, 2010.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO... More...
BioSpace, News, Syndication »
Halozyme Therapeutics, Inc. Begins Phase 2 Clinical Trials With Insulin Analogs Lispro and Aspart With rHuPH20 in Type 1 and Type 2 Diabetes | |
|
Posted by BioSpace.com Featured News September 1st, 2010 .
| |
| No Comments |
SAN DIEGO, Sept. 2 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active... More...
Recent Posts
- The Innovation Imperative: How Corporations and Nations Can Survive the Tsunami of Global Competition and Thrive
- Quality Assurance Manger – TriLink BioTechnologies – San Diego, CA
- Quality Assurance Manger – TriLink BioTechnologies – San Diego, CA
- Principal Industrial Microbiologist – San Diego, CA
- Principal Industrial Microbiologist – San Diego, CA
Most Commented
Recent Comments
- Benjamin Good on The Wonderful World of Wikis for Life Scientists
- Robert Landes on Confirmation for August SDBN Event
- Dan Gilliland on The Wonderful World of Wikis for Life Scientists
- Gregg Masters on Join Us at BarCamp in San Diego July 10/11
- Delmar Larsen on The Wonderful World of Wikis for Life Scientists
